Active, not recruitingInterventional · Phase 2NCT05242484 ↗A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
Active, not recruitingInterventional · Phase 2NCT05466890 ↗Phase 2a, Double-Blind, Randomized Adaptive Design, Placebo-Controlled, Parallel Group Study to Evaluate the Safety, Tolerability, Efficacy, PK and Biomarkers with Oral Colon Delivery PL8177 in Adult Subjects with Active Ulcerative ColitisDana Jeremy LukinPIInterventionDrug: PL8177 Placebo · Drug: PL8177DatesSep 2022 – Feb 2025SponsorPalatin Technologies, Inc.Ulcerative ColitisUlcerative Colitis AcuteUlcerative+1 more
Active, not recruitingInterventional · Phase 2NCT06109441 ↗Phase 2a, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of ALTB-268 in Subjects With Moderately to Severely Active Ulcerative Colitis Refractory to Biologic TherapyDana Jeremy LukinPIInterventionBiological: ALTB-268DatesDec 2023 – Mar 2026SponsorAltruBio, Inc.Ulcerative Colitis
Active, not recruitingInterventional · Phase 2NCT06257875 ↗A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative ColitisEllen J ScherlPIInterventionDrug: Lutikizumab · Drug: AdalimumabDatesMar 2024 – Sep 2027 (est.)SponsorAbbVie Inc.Ulcerative Colitis
RecruitingInterventional · Phase 2NCT07012395 ↗Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative ColitisDana Jeremy LukinPIInterventionDrug: SPY001 · Drug: SPY002 · Drug: SPY003 · Other: PlaceboDatesMay 2025 – Jun 2027 (est.)SponsorSpyre Therapeutics INCUlcerative ColitisInflammatory Bowel DiseasesColitis+1 more
Enrolling by invitationInterventional · Phase 2NCT07652294 ↗A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants With Inflammatory Bowel DiseaseDana Jeremy LukinPIInterventionDrug: SPY001 · Drug: SPY002 · Drug: SPY003DatesJun 2026 – Mar 2029 (est.)SponsorSpyre Therapeutics INCUlcerative ColitisInflammatory Bowel DiseasesColitis+1 more
CompletedInterventional · Phase 2NCT03558152 ↗A Phase II, Randomized, Parallel-Group, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study To Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and Compared With Vedolizumab in Patients With Moderate to Severe Ulcerative ColitisRandy LongmanPIInterventionDrug: UTTR1147A · Drug: UTTR1147A Placebo · Drug: Vedolizumab · Drug: Vedolizumab PlaceboDatesOct 2018 – Dec 2021· Results postedSponsorGenentech, Inc.Ulcerative Colitis
TerminatedInterventional · Phase 2NCT03893565 ↗A Multicentre Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety, Tolerability, Efficacy, Dose-response, Pharmacokinetics and Pharmacodynamics of Repeat Dosing of an Anti-LAG3 Cell Depleting Monoclonal Antibody (GSK2831781) in Patients With Active Ulcerative ColitisRandy LongmanPIInterventionDrug: GSK2831781 - Double Blind Phase · Drug: Placebo · Drug: GSK2831781 - Open Label phaseDatesMay 2019 – May 2021· Results postedSponsorGlaxoSmithKlineColitis, Ulcerative
CompletedInterventional · Phase 2NCT03998488 ↗A Randomized, Placebo-controlled Clinical Trial Examining the Efficacy of Fecal Microbiota Transplantation (FMT) and Subsequent Dietary Fiber in Patients With Moderate Ulcerative ColitisRandy LongmanPIInterventionDrug: Fecal Microbiota Transplantation · Dietary supplement: Psyllium Husk PowderDatesJan 2020 – Jun 2023· Results postedSponsorWeill Medical College of Cornell UniversityUlcerative ColitisInflammatory Bowel Diseases
CompletedInterventional · Phase 2NCT04996797 ↗A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Induction Therapy With PRA023 in Subjects With Moderately to Severely Active Ulcerative ColitisRandy LongmanPIInterventionDrug: Tulisokibart · Device: Companion Diagnostic (CDx) Testing · Other: PlaceboDatesJul 2021 – Jun 2023· Results postedSponsorPrometheus Biosciences, IncUlcerative Colitis
TerminatedInterventional · Phase 2NCT05370885 ↗Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of VE202 in Patients With Mild-to-Moderate Ulcerative ColitisDana Jeremy LukinPIInterventionBiological: VE202 · Drug: Vancomycin Oral Capsule · Other: VE202 Placebo · Other: Vancomycin PlaceboDatesMay 2023 – Aug 2025SponsorVedanta Biosciences, Inc.Ulcerative ColitisColitis, Ulcerative